Adalimumab biosimilar - Biocad

Drug Profile

Adalimumab biosimilar - Biocad

Alternative Names: BCD 057

Latest Information Update: 19 Aug 2016

Price : $50

At a glance

  • Originator Biocad
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 19 Jul 2016 Phase-III clinical trials in Plaque psoriasis in Russia (SC) (Biocad pipeline, July 2016; NCT02762955)
  • 19 Jul 2016 Phase-III clinical trials in Rheumatoid arthritis in Russia (SC) (Biocad pipeline, July 2016)
  • 08 Jun 2016 Pharmacokintic, adverse event and immunogenicity data from a phase I trial in Healthy vounteers presented at the 17th Annual Congress of the European League Against Rheumatism (ELAR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top